Important information for our community: | |||
| COVID-19 Resource Center | Your Care During the Pandemic | ||
About Holy Name Medical Center201-833-3000
877-HOLY-NAME (465-9626)
201-833-3300
201-833-3187
201-833-7040
201-833-3352
For general questions or comments, email info@holyname.org
Learn more about these studies:
|
|
|
Nearly half of all American adults have cardiovascular disease, making them more susceptible to a heart attack or stroke. Holy Name Medical Center is at the forefront of addressing this widespread condition with an array of advanced treatments for the disease, the number one killer of men and women in the U.S.
Holy Name is the only site in northern New Jersey offering the opportunity for eligible patients with cardiovascular disease to participate in the Select Semaglutide clinical study. This clinical trial is evaluating whether the medication, Semaglutide, is effective in preventing a recurrence of a cardiovascular event in patients who have suffered a heart attack, stroke or decreased circulation in their legs.
Semaglutide is approved by the Food and Drug Administration (FDA) to help control diabetes and has been shown to reduce the risk of cardiovascular events in those patients. The Select study is looking at whether the medication can reduce the risk in people who don't have diabetes but are mildly overweight and have cardiovascular disease. Semaglutide is added to whatever other medications might be used for controlling blood pressure and cholesterol.
"It has been shown that this medication causes mild weight loss and improvement of cholesterol when added to existing therapy in people with diabetes," said Dr. Thomas Birch, an internist and principal investigator of the study at Holy Name. "The Select study will evaluate whether it has the same effect on people without diabetes."
Individuals who think they might be eligible for this study should contact Holy Name's Institute for Clinical Research at 201-541-6312.
